Developer of off-the-shelf gene therapies using immune-shielded lentiviral vectors.
| Date | Round | Amount |
|---|---|---|
| Sep 2024 | Series B Genespire, a Milan gene-therapy biotech, raised a EUR46.6M Series B co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital. | $50.3M |